US 12,215,377 B2
HIV or HCV detection with CRISPR-CAS13A
Parinaz Fozouni, San Francisco, CA (US); Melanie Ott, Mill Valley, CA (US); and Jennifer A. Doudna, Oakland, CA (US)
Assigned to The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone, San Francisco, CA (US); and The Regents of the University of California, Oakland, CA (US)
Appl. No. 17/273,752
Filed by The Regents of the University of California, Oakland, CA (US); and The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone, San Francisco, CA (US)
PCT Filed Sep. 6, 2019, PCT No. PCT/US2019/049954
§ 371(c)(1), (2) Date Mar. 5, 2021,
PCT Pub. No. WO2020/051452, PCT Pub. Date Mar. 12, 2020.
Claims priority of provisional application 62/728,329, filed on Sep. 7, 2018.
Prior Publication US 2021/0348212 A1, Nov. 11, 2021
Int. Cl. C12Q 1/44 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12Q 1/68 (2018.01); C12Q 1/6806 (2018.01); C12Q 1/6876 (2018.01); C12Q 1/6888 (2018.01); C12Q 1/70 (2006.01)
CPC C12Q 1/6806 (2013.01) [C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12Q 1/6888 (2013.01); C12Q 1/703 (2013.01); C12N 2310/20 (2017.05); C12Q 2600/158 (2013.01)] 19 Claims
 
1. A method comprising:
(a) incubating a sample containing RNA with a Cas13a protein and at least one CRISPR guide RNA (crRNA) for a period of time to form a RNA cleavage product; and
(b) detecting a level of HIV or HCV RNA cleavage product with a detector,
wherein the RNA is not reverse transcribed prior to the detecting step,
wherein the least one crRNA is SEQ ID NOs: 1-8, 18-25 or 26.